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Synthetic pyrrole (P)-imidazole (I) containing polyam-
ides can target predetermined DNA sequences and
modulate gene expression by interfering with tran-
scription factor binding. We have previously shown
that rationally designed polyamides targeting the
inverted CCAAT box 2 (ICB2) of the topoisomerase
IIa (topo IIa) promoter can inhibit binding of tran-
scription factor NF-Y, re-inducing expression of the
enzyme in confluent cells. Here, the A/T recognizing
fluorophore, p-anisylbenzimidazolecarboxamido (Hx)
was incorporated into the hybrid polyamide HxIP,
which fluoresces upon binding to DNA, providing an
intrinsic probe tomonitor cellular uptake. HxIP targets
the 50-TACGAT-30 sequence of the 50 flank of ICB2
with high affinity and sequence specificity, eliciting
an ICB2-selective inhibition/displacement of NF-Y.
HxIP is readily taken up by NIH3T3 and A549 cells,
and detected in the nucleus within minutes. Expo-
sure to the polyamide at confluence resulted in a
dose-dependent upregulation of topo IIa expression
and enhanced formation of etoposide-induced DNA
strand breaks.
INTRODUCTION
Pyrrole-imidazole polyamides comprise a class of non-covalent
DNA binding ligands with programmable sequence recognition.
These agents can act as synthetic gene expression regulators by
interfering with the binding of a number of endogenous transcrip-
tion factors to their target DNA elements in designated pro-
moters. Polyamides can display affinities and DNA sequence
specificities rivaling those of native proteins (Trauger et al.,
1996; Dervan and Bu¨rli, 1999; Dervan and Edelson, 2003), and
have been successfully used for the modulation of gene expres-
sion in both cell culture (Dervan and Edelson, 2003; Raskatov
et al., 2012a, 2012b) and tumor xenografts (Raskatov et al.,
2012a, 2012b).
The ability of polyamides to induce a significant biological
effect requires effective nuclear localization. This remains a862 Chemistry & Biology 22, 862–875, July 23, 2015 ª2015 Elsevier Lchallenge given the considerable variation in cell permeability
across a range of mammalian cell lines dictated by polyamide
design, composition, and order of the heterocyclic imidazole
(I) and pyrrole (P) rings (Edelson et al., 2004; Best et al.,
2003). Conjugation to fluorescent dyes such as perylene,
thiazole orange, tetramethyl rhodamine, BODIPY, DAPI, and
fluorescein has aided the systematic study of polyamide
cellular uptake (reviewed in Vaijayanthi et al., 2012) and allowed
the identification of the structural modifications required to
enhance nuclear localization and biological effect. Such struc-
ture-uptake studies have contributed to further advancing the
potential of polyamides for in vivo applications (Meier et al.,
2012).
Topo IIa is an enzyme involved in multiple critical cellular
functions such as DNA replication, transcription, chromosome
segregation, recombination, and chromosome condensation
(Wang, 2002), and is the cellular target of chemotherapeutic
drugs used in the clinic, notably etoposide and doxorubicin
(Nitiss, 2009). Elevated levels of topo IIa confer increased
sensitivity to enzyme inhibitors, while decreased or altered
expression has been correlated with drug resistance (Son
et al., 1998; Lage et al., 2000; Wang et al., 1997; Dingemans
et al., 1998). Topo IIa levels, and therefore relative drug sensi-
tivity, vary according to the proliferation state of the cells and
can be cell density dependent (Tolner et al., 2001; Valkov
et al., 2000). The gene promoter has been characterized and
several regulatory elements identified, among which are five
CCAAT boxes in the inverted orientation (Hochhauser et al.,
1992). Deletion and mutation analysis revealed that the in-
verted CCAAT box 2 (ICB2, 50-ATTGG-30) is the critical DNA
binding element for the transcriptional downregulation of the
enzyme at confluence (Isaacs et al., 1996). The heterotrimeric
transcription factor NF-Y can have both inhibitory and stimula-
tory effects on gene regulation; however, it is the interaction
with ICB2 that exerts a negative regulatory effect and medi-
ates the repression of the promoter activity (Tolner et al.,
2001; Isaacs et al., 1996). The increased NF-Y association
with the topo IIa promoter at confluence and, in contrast, its
reduction upon treatment with an ICB2-targeting polyamide
are consistent with the repressive role of NF-Y (Hochhauser
et al., 2007).
Our research groups have previously employed the topo IIa
promoter as a model system for proof of principle of the
ability of polyamides to modulate gene expression in cellstd All rights reserved
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Figure 1. Design of the Fluorescent Poly-
amide, HxIP
(A) Structures of the non-fluorescing polyamides
PPIP and f-PIP, Hoechst 33258, whose p-ani-
sylbenzimidazolecarboxamido moiety is incorpo-
rated in HxIP, and the resulting fluorescent hybrid
polyamide HxIP.
(B) Schematic representation of HxIP binding to the
50-TACGAT-30 site on the 50 flank of ICB2.(Tolner et al., 2001; Le et al., 2006; Wells et al., 2006;
Hochhauser et al., 2007; Kotecha et al., 2008; Franks et al.,
2010).
In light of the poor nuclear localization often associated with
larger hairpin polyamides (Franks et al., 2010), we sought an
alternative polyamide motif based on the simple molecular
design of the triamides (Le et al., 2006). In this approach, the
p-anisylbenzimidazolecarboxamido (Hx) moiety of Hoechst
33258 has been attached to I-P heterocyclic units, generating
the hybrid polyamide HxIP, which significantly fluoresces only
upon binding to its genomic target (Figure 1A), facilitating the
direct readout of cellular uptake and DNA binding and negating
the need for the use of bulky fluorophores. We have reported
the design, synthesis, DNA binding, and fluorescent properties
of HxIP and related analogs elsewhere (Chavda et al., 2011).
The Hx component behaves similarly to two consecutive pyrrole
rings (PP) or (f-P), comprising a valid alternative recognition unit
and rendering HxIP a fluorescent equivalent of its predecessors
f-PIP and PPIP (Figure 1A). HxIP binds to its consensus
sequence in a 2:1 fashion as an overlapped stacked dimer
(Figure 1B). The consensus sequence is found to overlap ICB2
(Figure 1B), therefore making it selective for inhibition of the
NF-Y/ICB2 interaction and transcriptional de-repression of the
topo IIa promoter.Chemistry & Biology 22, 862–875, July 23, 20RESULTS
DNA Binding of HxIP and Related
Polyamides on the topo IIa Promoter
The DNA sequence specificity and binding
affinity of HxIP for its target sequence 50-
TACGAT-30 have been previously ascer-
tained in a set of engineered DNA fragments
containing cognate and non-cognate bind-
ing sites (Chavda et al., 2011). Here, we
investigated the in vitro binding of HxIP
within the biologically relevant sequence of
the human topo IIa promoter using DNase I
footprinting and compared it with the bind-
ing of f-PIP and PPIP as well as the bis-
benzimidazole fluorophore Hoechst 33258.
The resolvable part of the gels, presented
in Figure 2, corresponds to the promoter re-
gion containing the ICB1 and the critical
ICB2 motif where the HxIP target sequence
is embedded in its 50 flank (Figure 2A).
Hoechst 33258, as previously reported (Tol-
ner et al., 2001), exhibits sequence speci-
ficity for AT-rich sequences located 30 to
the ICB1 and ICB2 sequences, with a major protected region at
50-TATA-30 becoming evident at 3 mM (Figure 2B). PPIP was the
least reactive compound, withweak non-specific footprints iden-
tified only at the highest drug concentrations tested (30 and
50 mM) (Figure 2C).We havepreviously reported that the incorpo-
ration of the formamido (f-) group at theN terminus of polyamides
increases binding affinity compared with their non-formamido
counterparts (Lacy et al., 2002). Consistent with this finding, f-
PIP exhibited enhanced binding affinity over the tetraamide
PPIP, binding at the preferred sequence 50-TACGAT-30 at con-
centrations as low as 3 mM (Figure 2D). Regions of cleavage inhi-
bition located at the upper portion of the autoradiogram are also
observable. HxIP demonstrated improved affinity over f-PIP and
greater DNA sequence selectivity (Figure 2E). A single strong
footprint at the target sequence emerged at 1 mM, while no other
major protection sites were evident up to 20 mM. These results
corroborate the original findings that the Hx moiety mimics the
PP or f-P recognition properties while imparting a higher binding
affinity for the consensus sequence (Chavda et al., 2011).
HxIP Preferentially Inhibits Protein Binding to the
ICB2 Motif
Electrophoretic mobility shift assays (EMSAs) were performed
to investigate the effects of HxIP on the in vitro binding of15 ª2015 Elsevier Ltd All rights reserved 863
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Figure 2. In Vitro DNA Binding of HxIP and
Related Polyamides to the topo IIaPromoter
(A) The sequence of topo IIa promoter containing
the ICB1-2 (black boxes) and the target sequence
(dashed-red box).
(B–E) Autoradiograms of DNase I footprinting gels
corresponding to Hoechst 33258 (B), PPIP (C),
f-PIP (D), and HxIP (E). The cleavage products of
the DNase I digestion reactions were resolved on
6% polyacrylamide gels. The concentrations (mM)
used are shown at the top of each gel. 0, controlled
cleavage reaction containing no drug. G + A
represents a marker specific for purines. The po-
sitions of ICB1, ICB2, and detected footprints are
indicated by solid bars. Asterisks denote the
concentration at which footprints become evident.
864 Chemistry & Biology 22, 862–875, July 23, 2015 ª2015 Elsevier Ltd All rights reserved
AC
D
B Figure 3. Effect of HxIP on NF-Y Interaction
with the ICB Motifs of the topo IIa Promoter
EMSAs using oligonucleotides containing the five
ICBs present in the topo IIa promoter were incu-
bated with increasing concentrations of poly-
amides for 1 hr at room temperature prior to
the addition of nuclear extracts from cultured
confluent NIH3T3 cells. 0, control reaction con-
taining the probe and nuclear extracts with no drug
added; C, reaction in the presence of an excess of
unlabeled competitor oligonucleotide of the same
sequence as the control reaction; M, reaction in the
presence of an excess of unlabeled competitor
oligonucleotide bearing a mutation in the ICB
motif.
(A) Inhibitory effect of HxIP on protein binding to
the ICB2 after pretreatment with the polyamide.
(B) EMSA showing the ability of HxIP to displace
NF-Y bound to ICB2, with the addition of the
polyamide after a 1 hr preincubation of the extracts
with the radiolabeled probe.
(C) Comparative analysis of the inhibitory effects of
HxIP on NF-Y binding to the remaining inverted
CCAAT boxes ICB1, ICB3, ICB4, and ICB5. The
involvement of NF-Y in the protein complex bound
to the radiolabeled probes was confirmed with
supershift experiments using an anti-NF-Y(A)
antibody resulting in a supershifted protein/DNA
complex, indicated by an arrow (S). The specificity
of the supershift was further probed with the use
of an antibody specific for another transcription
factor (Sp1) (S0). Only the reactions with the NF-
Y(A) antibody yielded a supershifted complex.
(D) Effects of PPIP (left) and f-PIP (right) on the
binding of NF-Y containing protein complexes to
the ICB2.protein complexes to the ICB motifs on the topo IIa promoter.
Radiolabeled oligonucleotides containing each of the ICBs and
their flanking sequences, along with mutated controls, were
incubated with nuclear extracts prepared from cultured
confluent NIH3T3 cells (Figure 3). The presence of NF-Y in
the protein complex bound to the ICBs was identified by super-
shift analysis using an antibody specific to NF-YA (Figure 3C;
supershift denoted by an arrow). HxIP was able to abrogate
the NF-Y binding on ICB2, at doses R3 mM (Figure 3A). In par-
allel experiments, HxIP displaced NF-Y already bound to the
ICB2, when the probe was incubated with the nuclear extracts
prior to the addition of the compound (Figure 3B). No marked
abolition of protein binding was observed for the other ICBs,
except in the case of ICB3 where partial inhibition is evidentChemistry & Biology 22, 862–875, July 23, 2015only at the highest HxIP concentrations
(50 and 100 mM) (Figure 3C). The triamide
f-PIP exhibited similar ability to prevent
NF-Y binding to ICB2, while PPIP did
not have any effect even at 100 mM (Fig-
ure 3D), mirroring the binding affinities of
the polyamides displayed by DNase I
footprinting. These EMSA studies further
verified the high sequence selectivity of
HxIP for its cognate sequence as low
concentrations of HxIP selectivelyabolish the NF-Y binding, only to the ICB2-containing
oligonucleotide.
HxIP Cellular Uptake and Nuclear Localization
One of the challenges hindering the development of polyam-
ides as gene-regulatory agents is their often poor cellular up-
take and limited nuclear localization. HxIP, through the Hx moi-
ety, displays induced fluorescence upon excitation and binding
to its cognate sequence on double-stranded DNA (Chavda
et al., 2011). Exploiting this intrinsic property, we used confocal
microscopy to assess the nuclear uptake of the polyamide,
initially in NIH3T3 cells. Figure 4A (top) shows representative
images of cells exposed for 5 min to increasing concentrations
of the polyamide. HxIP nuclear staining is evident at 10 mM andª2015 Elsevier Ltd All rights reserved 865
A1 hr treatment
24 hr treatment
Figure 4. Visualization and Quantification of
HxIP Nuclear Localization
(A) NIH3T3 cells were treated with the indicated
concentrations of HxIP for 5 min, 1 hr, and 24 hr,
washed with PBS, and fixed with 4% para-
formaldehyde (PFA). They were subsequently
permeabilized and the nuclei were stained with
propidium iodide (PI) prior to confocal microscopy
observation. Images include the overlay of HxIP
with PI (composite). No HxIP signal was detected in
the control, untreated samples under the same
observation settings. The histograms on the right
correspond to NIH3T3 cells analyzed by a MoFlo
Legacy cell sorter with the fluorescence detected
by the appropriate bandpass filter. A region in the
histograms is identified that corresponds to the
cut-off point of the basal fluorescence of untreated,
control cells. Treatment conditions were identical
to the confocal images on the left.
(B) Assessment of nuclear colocalization of the PI
and HxIP was performed using the Coloc2 plugin
within the image analysis software, Fiji (ImageJ) to
calculate the Pearson correlation coefficient. In-
tensity profiles of the polyamide and PI fluores-
cence signal were generated using the LSM510
software.
(C) Intracellular distribution of HxIP in live, unfixed
NIH3T3 cells visualized by confocal microscopy
after 24 hr of incubation with increasing concen-
trations of polyamide. Cells were counterstained
with the red-fluorescent Mitotracker dye, which
selectively stains mitochondria. The composite
image presents the superimposed HxIP fluores-
cence and the Mitotracker fluorescence.
See also Figure S2.becomes more prominent at the higher concentration of 50 mM.
Nuclear accumulation was determined by the colocalization of
the polyamide fluorescence signal (blue) and propidium iodide
(PI) (red). To further corroborate the confocal microscopy ob-
servations, NIH3T3 cells treated under identical conditions
were quantitatively analyzed using a MoFlo cell sorter. As
shown in the derived corresponding histograms, a dose-
dependent shift in the median intensity of the distribution of
the treated cell population occurs when compared with the
‘‘basal levels’’ of the DMSO-treated controls. It is noteworthy
that the median intensity of the emitting fluorophore in the total866 Chemistry & Biology 22, 862–875, July 23, 2015 ª2015 Elsevier Ltd All rights reservedcell population analyzed increased by
1.2- and 2.6-fold, respectively, after
treatment with 10 mM and 50 mM for
5 min, compared with the DMSO-treated
controls. Similar results were obtained
with a longer incubation time of 1 hr (Fig-
ure 4A, middle). Next, we investigated
whether HxIP continues to concentrate
and/or remain in the nucleus during
longer exposure times, considering that
it binds to its nucleic acid substrate in a
reversible, non-covalent fashion. Contin-
uous presence of the polyamide for
24 hr (Figure 4A, bottom) results in prom-
inent nuclear staining at 10 mM with asubstantial shift of the relative intensity of the cell distribution.
The median fluorescence intensity of the cell population
increased 14.6-fold after treatment with 10 mM, and 24.7-fold
with 50 mM HxIP at 24 hr, compared with the untreated con-
trols. The colocalization of the HxIP and PI signals was quanti-
fied for the images in Figure 4B displaying Pearson correlation
coefficient values of 0.84 and 0.83 for NIH3T3 cells treated with
10 and 20 mM HxIP for 24 hr, respectively. The direct observa-
tion is complemented by the intensity profiles of the blue and
red fluorescence outputs along the xy axis indicated in the
images.
BC
Figure 4. (continued).We subsequently examined the intracellular distribution of
HxIP in A549 non-small cell lung cancer cells, deriving cell distri-
bution profiles similar to those of mouse NIH3T3 cells. According
to the flow cytometric analysis (Figure S1A), treatment with
50 mM of the polyamide results in a 3.5-fold increase in the me-
dian fluorescence intensity of the cell population after a 20-minChemistry & Biology 22,treatment and a 4.5-fold increase after 1 hr, compared with the
untreated controls (Figure S1B). At 24 hr, the increase of the fluo-
rescence intensity in the cell population continuously exposed to
HxIP was 20-fold (data not shown).
The preferential accumulation of the polyamide in the nu-
clear compartment was demonstrated using the cell-permeant862–875, July 23, 2015 ª2015 Elsevier Ltd All rights reserved 867
Figure 5. Cellular Assessment of the Sequence Specificity of HxIP-DNA Binding
Nuclear uptake of HxIP in A549 cells after a 3.5-hr pretreatment with the formamido triamides f-PIP (possessing identical DNA sequence specificity; left) and f-IPI
(possessing distinct DNA sequence specificity; right). HxIP was allowed to be taken up by the cells for a further 1 hr. Cells were washed, fixed, permeabilized, and
counterstained with PI. The HxIP fluorescence signal was detected by confocal microscopy. No fluorescence was exhibited by either f-PIP or f-IPI alone (middle
panels left and right, respectively). In contrast, strong staining was detected in the control panel of HxIP alone (top right) and in the cells pretreatedwith 20 mM f-IPI
(bottom right panel). f-PIP diminished HxIP staining, presumably through competitive binding exclusion (bottom left panel).Mitotracker Red probe, which selectively stains mitochondria.
Figure 4C shows the HxIP fluorescence concentrating in the
unstained areas of live, unfixed NIH3T3 cells after 24 hr of
exposure to the agent. Nuclear staining is displayed at
10 mM and becomes more pronounced at 20 mM. Nuclear-
exclusive HxIP accumulation was also detected in fixed
NIH3T3 and A549 cells (Figure S2). Taking these data
together, it is evident that there is a clear time- and dose-
dependent nuclear uptake of HxIP in both NIH3T3 and A549
cells.
Assessing the Sequence Specificity of DNA Binding of
Fluorescent Polyamides in Cells
Competition binding experiments using non-fluorescing coun-
terparts of known consensus sequences were performed to
probe the sequence-specific DNA binding of HxIP directly in
cells. Figure 5 shows A549 cells exposed to 20 mM f-PIP
(cognate sequence 50-TACGAT-30) or f-IPI (cognate sequence
50-ACGCGT-30) for 3.5 hr before treating for a further 1 hr with
50 mM HxIP. Neither of the formamido triamides possesses
inherent fluorescence, while HxIP yields strong staining in the
nucleus at the doses tested, as shown in the confocal images
(Figure 5, top and middle). Pretreatment with f-PIP inhibits868 Chemistry & Biology 22, 862–875, July 23, 2015 ª2015 Elsevier LHxIP from binding to the shared cognate target sites, as inferred
by the diminished fluorescent signal detected (Figure 5, bottom
left). Provided that the previously established sequence speci-
ficity of f-PIP (Buchmueller et al., 2005) is preserved in the
cellular environment, it can be assumed that f-PIP competes
with HxIP for the same nuclear sequences. In contrast, pretreat-
ment of A549 cells with f-IPI did not have any effect on the HxIP
nuclear staining (Figure 5, bottom right). Although f-IPI has a
higher binding affinity than f-PIP, based on the central pairing
rules (Buchmueller et al., 2005), its specificity for a distinct
DNA sequence does not exclude HxIP binding to its cognate
sequence.
HxIP Stimulates Topo IIa Expression in Confluent
NIH3T3 and A549 Cells
Having demonstrated that HxIP is readily taken up by cells and
localizes in the nucleus, its ability to modulate the expression
of topo IIa in confluent NIH3T3 and A549 cells was subsequently
assayed by immunoblotting. Confluence-induced downregula-
tion of topo IIa is well established in NIH3T3 cells (Tolner et al.,
2001) and is shown in Figure 6A, with significantly lower protein
levels detected in the nuclear fraction of confluent (CON)
compared with exponentially growing (EXPO) cells. Exposuretd All rights reserved
of confluent cells to increasing concentrations of HxIP for 18 hr
resulted in a dose-dependent upregulation of topo IIa.
The protein levels and subcellular distribution of topo IIa was
also examined by immunofluorescence microscopy (Figure 6B).
Cellular topo IIa resides predominantly in the nucleus of expo-
nentially growing NIH3T3 cells (Figure 6B, left) while at conflu-
ence the overall amount of topo IIa is drastically attenuated,
and the majority of the enzyme is exported and located in the
cytoplasmic compartment (Figure 6B, middle). This observation
is reminiscent of the cell density-dependent intracellular traf-
ficking and concomitant decrease in topo IIa levels reported
for other non-transformed cell lines, such as Chinese hamster
ovary and human fibroblasts (Valkov et al., 2000). Treatment of
confluent cells with HxIP for 18 hr results in markedly increased
nuclear topo IIa staining (Figure 6B, right), mirroring the results
obtained by immunoblotting and verifying the stimulatory effect
of HxIP.
Transition from log to plateau density cells has also been
shown to result in a cell density-dependent, nuclear-cyto-
plasmic translocation of topo IIa in leukemic and human
myeloma cell lines. In tumor cells the cytoplasmic compartment
had significantly more topo IIa than the nucleus at confluence;
however, the overall amount of protein was comparable with
that of log-phase cells (Valkov et al., 2000; Engel et al., 2004).
Cytoplasmic distribution of topo IIa has been also observed in
multicell spheroids and xenograft tumors, as opposed to pri-
marily nuclear localization in cell monolayers of Chinese ham-
ster V79 lung fibroblasts, rat C6 glioma cells, and SiHa human
cervical carcinoma cells (Oloumi et al., 2000). Flow cytometric
analysis has previously determined the topo IIa mRNA levels
in high-density quiescent A549 cells to be 3-fold lower than in
proliferating cells (Leonce et al., 1996). Figure 6C confirms the
distinct subcellular distribution of topo IIa between the two
proliferation states in A549 cells, as detected by confocal
microscopy, while the immunoblot in Figure 6D shows that
the nuclear topo IIa levels are markedly greater in exponentially
growing than in confluent cells. Treatment with increasing
doses of HxIP resulted in re-induced expression of topo IIa
in vitro at the protein and mRNA level (Figures 6D and 6E) in
confluent A549 cells.
Potentiation of the Etoposide DNA-Damaging Effects
by HxIP
HxIP increases the levels of nuclear topo IIa and, therefore, the
target of drugs such as etoposide. We subsequently investi-
gated the enhancement of etoposide-mediated DNA damage
in confluent A549 cells. Confocal microscopy was used to
reveal the induction of g-H2AX foci, resulting from etoposide-
generated DNA double-strand breaks (DSBs). Cells were
grown to confluency and were pretreated with increasing con-
centrations of HxIP for 18 hr before exposing them to 50 mM
etoposide for 2 hr. Cells were allowed to recover in drug-free
medium for 24 hr before staining for g-H2AX. As shown in Fig-
ure 7A, HxIP alone does not produce a significant level of g-
H2AX foci above background, as it non-covalently binds to
DNA and does not produce DNA strand breakage. Combina-
tion treatments consistently produced numerically more g-
H2AX foci (an average of 3.5 and 4 foci per nuclei with 1 mM
and 2 mM HxIP, respectively) than etoposide alone (1.6 fociChemistry & Biology 22,per nuclei), as quantified by the CellProfiler software
(Figure 7B).
The increased levels of etoposide-induced g-H2AX in HxIP-
treated confluent cells were also shown by immunoblotting (Fig-
ure 7C). The sustained, dose-dependent upregulation of topo IIa
afforded by HxIP coincided with a parallel increase in g-H2AX
protein levels, in combination treatments with etoposide. In the
latter, depletion of the topo IIa band is attributed to intracellular
trapping of the enzyme via the formation of transient covalent
topo IIa-DNA complexes, stabilized by etoposide. The resulting
higher molecular weight and lower mobility of these complexes
during electrophoresis prevents the normal migration of topo
IIa (Hsiang and Liu, 1988; Sorensen et al., 1999). Similar results
were obtained in confluent NIH3T3 cells (Figures S3A and S3B).
Finally, pretreatment of confluent A549 cells with 5 mM HxIP
resulted in cellular chemosensitization to etoposide, compared
with etoposide treatment alone, as determined by the sulforhod-
amine B (SRB) assay (Figure 7D). No cytotoxic effect by HxIP
alone was observed with this assay in exponential or confluent
A549 and NIH3T3 cells, either for 18 hr or continuous 96 hr treat-
ments, at 100 mM.
DISCUSSION
In our strategy to design cell-permeable, high-affinity, sequence-
specific DNA binding agents for the chemical control of topo IIa
transcription, we have previously applied the side-by-side het-
erocyclic DNA recognition rules in the design of polyamides,
achieving varying recognition fidelities, affinities, and biological
effects. We now return to the simpler triamides exemplified by
f-PIP, possessing the most favorable DNA binding properties
for targeting the ICB2 of the gene promoter (Le et al., 2006).
As the repertoire of the DNA recognition functionalities con-
tinues to broaden, here we explore an alternative design, in
which the fluorophore moiety (Hx) represents a constituent
part of the recognition module of the hybrid polyamide. In the
past, conjugation of a fluorophore often had an undesired ef-
fect on the DNA binding affinities of the resulting polyamides
(Best et al., 2003). DNase I footprinting analysis confirmed
the legitimacy of the use of Hx as a valid alternative to the
f-P and PP moieties, and highlighted the retention of binding
specificity and affinity of HxIP for its cognate sequence.
EMSA studies revealed the increased selectivity of HxIP to
disrupt NF-Y binding to the biologically relevant ICB2 element.
In some of our previous efforts, polyamides were rationally de-
signed to unambiguously bind to the core CCAAT motif. HxIP,
however, was designed to bind to an overlapping sequence
occurring solely at the ICB2 in the promoter, allowing for
specificity.
The improved selectivity of HxIP for ICB2 is complemented
with the ability of the molecule to exhibit increased fluores-
cence upon binding to its target DNA sequence, acting as an
intrinsic probe for monitoring cellular uptake, nuclear accessi-
bility, and interaction with genomic DNA. To our knowledge,
the benzimidazole furamidine analog DB293 represents the
only other example of a fluorescent rationally designed and
sequence-specific compound, interacting with DNA by forming
a stacked dimer in the minor groove and preferentially accumu-
lating in the nucleus. In sharp contrast to HxIP, however,862–875, July 23, 2015 ª2015 Elsevier Ltd All rights reserved 869
AC D
E
B
(legend on next page)
870 Chemistry & Biology 22, 862–875, July 23, 2015 ª2015 Elsevier Ltd All rights reserved
DB293 fluorescence decreases upon binding to DNA (Lansiaux
et al., 2002). In addition, the Dervan group have reported the
incorporation of fluorescent moieties such as benzimidazole,
hydroxybenzimidazole, and imidazopyridine as an integrated
part of the recognition modules of hairpin polyamides (Cheno-
weth et al., 2007).
Previous studies of the in vitro interaction of the polyamides
with the topo IIa promoter utilized numerous biophysical assays.
Cellular permeation and promoter interaction were indirectly
assumed by increased levels of topo IIa in confluent cells as as-
sessed by immunoblotting, chromatin immunoprecipitation, and
cellular sensitization to etoposide (Hochhauser et al., 2007; Le
et al., 2006; Kotecha et al., 2008). In this study, the nuclear accu-
mulation and DNA binding of the polyamide is directly verified
by detecting the increased fluorescence output. HxIP rapidly
localizes in the nucleus of different cell types in a dose- and
time-dependent manner. Fast uptake (15 min) of a fluorescent
polyamide by cells in culture has also been reported elsewhere
(Matsuda et al., 2011), while another fluorescent hairpin poly-
amide was retained and detected in xenograft tumor-derived
cells days after injection in mice (Raskatov et al., 2012a,
2012b). HxIP was able to upregulate topo IIa gene expression
in both NIH3T3 and A549 cells and appears to do so by selec-
tively targeting the confluence-specific resistant phenotype, as
it is only effective in the context of cellular confluency while hav-
ing no effect on exponentially growing cells (Figures 6 and S4).
The confluence-induced topo IIa downregulation produces
resistance to topo IIa poisons due to attenuation of the drug
target and the ensuing reduction in the cleavable complexes
formed and processed, which limits the DNA damage response
and, ultimately, the cellular apoptotic response. The ability of
HxIP to increase the levels of active enzyme in the nucleus,
through transcriptional de-repression of the gene promoter, re-
sulted in potentiation of the DNA-damaging effects of etoposide,
as observed by the increase in the phosphorylation of H2AX in
combination treatments (Figures 7 and S3). Etoposide is consid-
ered a potent DNA DSB inducer, with the g-H2AX levels accu-
rately reflecting the number of DSBs and serving as a surrogate
marker of cell killing (Smart et al., 2008). The marked effect of
HxIP on H2AX activation shown here in combination with etopo-
side also translated into cellular re-sensitization due to the
enhancement of the cytotoxic potency of the inhibitor. HxIP
does not form adducts with DNA, as it interacts non-covalently
without evidence of DNA damage. No significant DNA fragmen-
tation was detected by the alkaline single cell gel electrophoresis
assay (comet assay; data not shown) in HxIP-treated cells, and
only low levels of phosphorylation of H2AX were detected by
immunofluorescence and immunoblotting in the polyamide-
only treatments (Figures 7 and S3). These observations areFigure 6. Effect of HxIP on Topo IIa Expression in Confluent NIH3T3 a
(A) Immunoblot analysis of NIH3T3 nuclear extracts probed with a topo IIa antibod
(CON), and treated with increasing concentrations of HxIP for 18 hr.
(B) Topo IIa subcellular localization in exponentially growing, confluent, and HxIP-
probed with anti-rabbit topo IIa antibody, and stained with Alexa Fluor 488 (topo
sequential scanning images.
(C) Topo IIa subcellular localization of exponentially growing and confluent A549
(D) Immunoblotting of A549 nuclear extracts as in (A).
(E) Quantification of topo IIa mRNA via RT-PCR analysis, after treatment with inc
Chemistry & Biology 22,consistent with those recently reported for an eight-ring Py-Im
polyamide designed to target the prostate-specific antigen pro-
moter via the androgen response element. This polyamide also
showed no evidence of direct DNA damage other than a faint
phosphorylation of H2AX in immunoblots, yet exhibited in vivo
anti-tumor efficacy against prostate cancer xenografts with
limited host toxicity (Yang et al., 2013).
There is inconclusive evidence for the use of topo IIa levels as
a molecular determinant of therapeutic response from clinical
studies, although in several of those, overexpression of topo
IIa was shown to correlate with a favorable response to anthra-
cycline and doxorubicin therapy for breast cancer (Coon et al.,
2002; Cardoso et al., 2004; Durbecq et al., 2004). Conversely,
suppression of topo IIa has been confirmed to produce resis-
tance using an RNAi-based screening approach in a lymphoma
mouse model. ShTopo IIa-mediated downregulation of the
enzyme caused resistance to etoposide in vitro and to doxoru-
bicin in vivo. The levels of topo IIawere shown to be dramatically
reduced in post-doxorubicin treated relapsed tumors compared
with any untreated lymphomas, rendering topo IIa levels a major
molecular determinant of therapeutic response for doxorubicin
(Burgess et al., 2008). It is therefore envisaged that non-toxic
agents such as HxIP could be used to chemosensitize cells
by effectively reconstituting sufficient levels of active enzyme,
offering an alternative strategy to reverse acquired resistance
to clinically used topo IIa poisons.
The Dervan group has conducted extensive structure-uptake
relationship studies of fluorescent polyamides and have dis-
cerned the key features/modifications that favor nuclear uptake
and gene-regulatory activity, with a particular emphasis on the
hairpin configuration (Edelson et al., 2004; Best et al., 2003; Me-
ier et al., 2012). Fluorescent analogs of eight-ring hairpin poly-
amides shown to modulate gene expression in tumor models
have been used to monitor the distribution of the parent polyam-
ides in various organ tissues. Fluorescence localization of the
analogs in sections of tumor tissue resembled that observed in
tumor-derived cells and cell culture (Nickols et al., 2013). HxIP
represents a distinct polyamide design, also offering a high
degree of selective nuclear accumulation in cultured cells. As
with the fluorescein isothiocyanate conjugates, the fluorescent
properties of HxIP could be utilized to systematically monitor
the distribution of polyamide in organs and tissues, and investi-
gate any preferential accumulation in tumor sites. A detailed
assessment of the pharmacokinetic and pharmacodynamics
properties of HxIP as well as the study of the genome-wide ef-
fects is warranted to further establish its potential for use in com-
bination with topo IIa inhibitors. The study of the genome-wide
effects of HxIP is also necessary to evaluate potential off-target
effects resulting from promiscuous polyamide binding acrossnd A549 Cells
y. Cells were either exponentially growing (EXPO) or maintained at confluency
treated confluent NIH3T3 cells for 18 hr. Cells were washed, fixed with 4%PFA,
IIa) and PI (nucleus). Nuclei are presented from middle sections of a stack of
cells. In this case, nuclei were stained with DAPI.
reasing concentrations of HxIP. Data are represented as mean ± SEM (n = 3).
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Figure 7. HxIP-Mediated Enhancement of the DNA-Damaging Effects of Etoposide
(A) A549 cells were pretreated with the indicated concentrations of HxIP for 18 hr alone or exposed to 50 mM etoposide for a further 2 hr. After 24 hr in drug-free
medium, they were analyzed for g-H2AX levels by immunofluorescence confocal microscopy.
(B) Average number of g-H2AX per nuclei for the indicated treatments. Fifty nuclei per experimental condition, from three independent biological repeats, were
used for quantification by CellProfiler software. Data are represented as mean ± SEM (n = 3). Asterisks show statistical significance (p < 0.05).
(C) Immunoblotting of the nuclear levels of g-H2AX and topo IIa, 24 hr after pretreatment with HxIP for 18 hr and/or treatment with etoposide for 2 hr and their
combination. See also Figure S3.
(D) Cellular sensitivity assessed using the SRB assay. Error bars represent the SEM from three replicates. Asterisk shows statistical significance (p < 0.05).
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the human genome, due to the limited size of the consensus
sequence. The Dervan group have demonstrated the remark-
able specificity of 6-bp targeting polyamides, with minimal
changes to the gene expression observed across the transcrip-
tome in cell culture and xenograft models, indicating that smaller
polyamides can still yield targeted biological effects (Raskatov
et al., 2012a, 2012b).
HxIP provides the framework for a new series of fluorescent
DNA reading molecules, which can target specific protein-DNA
interactions and modulate the expression of selected target
genes. Another example, an Hx analog of our previously
described f-IPI triamide, has been successfully used to target
the Mlu1 cell cycle box (MCB) sequence (50-ACGCGT-30), inhibit
transcription factor binding, and reduce the expression of the
HuCdc7/Dbf4 target gene (unpublished data in preparation).SIGNIFICANCE
HxIP represents an alternative design for polyamides, incor-
porating the Hx fluorophore within its DNA recognition
framework, as a valid alternative to the conventional PP
and f-P moieties while deviating from the strategy of attach-
ing bulky fluorophores to afford fluorescent polyamides.
HxIP selectively binds to the ICB2 of the human topo IIa pro-
moter and effectively disrupts the NF-Y-ICB2 interaction,
which is implicated in the confluence-induced transcrip-
tional downregulation of the enzyme. By virtue of its
inherent fluorescent properties, polyamide nuclear uptake
and in situ sequence-selective genomic binding can now
be directly assessed without solely relying on a relevant
biological readout. HxIP rapidly accumulates in the nucleus
and re-induces the expression of topo IIa at mRNA and pro-
tein levels in confluent fibroblasts and cancer cells. The
topo IIa upregulation results in the potentiation of the eto-
poside-induced DNA-damaging effects, and highlights the
potential of HxIP for its use in combination with topo IIa poi-
sons as a chemosensitizing agent within the context of
cellular confluency.EXPERIMENTAL PROCEDURES
Chemicals
HxIP and relevant polyamides were synthesized as previously described (Le
et al., 2006; Chavda et al., 2011) and were dissolved in DMSO (BDH) as
were etoposide and Hoechst 33258 (Sigma-Aldrich).Cell Lines and Culture Conditions
NIH3T3 mouse fibroblast cells were obtained from CR-UK London Research
Institute, and the A549 cell line was purchased from the European Collection
of Cell Cultures. All cell lines were maintained in DMEM (PAA) supplemented
with 2 mM L-glutamine (PAA) and 10% fetal bovine serum (PAA). Growth inhi-
bition was determined in both exponentially growing and confluent cells using
the SRB assay as previously described (Kiakos et al., 2007).DNase I Footprinting
The preparation of the 50-radiolabeled DNA substrate corresponding to the
topo IIa promoter by PCR amplification, isolation, and purification have been
reported previously (Tolner et al., 2001). The DNase I footprinting reactions
were modified in this study, and carried out as described by Chavda et al.
(2011).Chemistry & Biology 22,Preparation of Protein Extracts
Nuclear extracts were prepared using the Active Motif Nuclear extract kit
following the manufacturer’s protocol. All steps were carried out in the pres-
ence of protease inhibitor mix (13 Complete, Roche) and phosphatase inhib-
itor (13 phosSTOP, Roche).
EMSA
The oligonucleotides (Eurofins MWG Operon) containing the inverted ICBs
used in the EMSA assays are listed in Table S1. Experiments were conducted
as described by Hochhauser et al. (2007).
Immunoblotting
40 mg of nuclear extracts were denatured by heating for 5 min at 95C in sam-
ple buffer containing 100 mM Tris-Cl (pH 6.8), 4% SDS, 10% 2-mercaptoe-
thanol, 20% glycerol, and 0.02% bromophenol blue. Precision Plus Protein
Dual color standards (Bio-Rad) were used as a molecular weight reference.
For the detection of topo IIa, proteins were separated on a NuPAGE 7%
Tris-acetate gel (Life Technologies) and subsequently transferred to polyviny-
lidene difluoride membranes (Immobilon-P transfer membrane; Millipore).
Membranes were blocked for 1 hr at ambient temperature in a blocking buffer
containing 5% (w/v) non-fat dry milk in 13 Tris-buffered saline and 0.1%
Tween 20. Topo IIa was identified by incubation in a 1:200 dilution of a
topo IIa goat polyclonal antibody (Santa Cruz Biotechnology) in blocking
buffer overnight at 4C and subsequent incubation for 1 hr with a rabbit
anti-goat secondary antibody (Santa Cruz Biotechnology) at a dilution of
1:5,000. Antibody binding was visualized by enhanced chemiluminescence
(Amersham) on autoradiography film (Kodak-X-Omat). For the detection of
phosphorylated histone H2A.X (Ser139), proteins were separated on a
NuPAGE 10% Bis-Tris gel and probed using the anti-phospho-Histone
H2A.X monoclonal antibody (Millipore) at a 1:1,000 dilution. Lamin A/C was
used as loading control.
Quantitative Real-Time PCR
RNA was isolated from confluent untreated and HxIP-treated A549 cells using
the RNeasy Plus Mini kit (Qiagen). cDNA generation was carried out using the
High-Capacity cDNA Reverse Transcription kit (Applied Biosystems). Real-
time PCR was carried out using the ABI PRISM 7000 Sequence Detection
System (Applied Biosystems) and Taqman assay probes (Life Technologies)
for the target gene, topo IIa (Hs01032137_m1) and the internal control for all
reactions, glyceraldehyde-3-phosphate dehydrogenase (Hs03929097_g1).
The relative quantification of topo IIa gene expression was determined using
the 2DDCt method and normalized to the internal control. For comparison,
levels of topo IIa mRNA in untreated samples were set at 1, and all treated
samples were expressed as relative fold changes.
Immunofluorescence Staining
For topo IIa staining, 2.5 3 104 cells/ml were plated on 13-mm glass cover-
slips (VWR) in 24-well plates, allowed to adhere, and processed either while
growing exponentially or at confluency. Confluent cells were treated with
HxIP for 18 hr, followed—when assayed for g-H2AX—by etoposide for
2 hr. Cells were washed in ice-cold PBS and fixed with 4% paraformalde-
hyde (PFA; Alfa Aesar) for 10 min at room temperature, followed by perme-
abilization with PBS containing 0.5% Triton X-100 for 10 min. Cells were
blocked in PBS 5% BSA (Sigma-Aldrich) for 1 hr at ambient temperature.
Respective proteins were identified by incubation with anti-topo IIa (1:250)
(kindly provided by Dr. I.D. Hickson) and anti-phospho-Histone H2A.X
mouse monoclonal (1:500; Millipore). Cells were incubated with a secondary
fluorescent conjugated goat anti-mouse antibody Alexa Fluor 488 (1:500; Life
Technologies) for 2 hr at room temperature. Nuclei were stained using PI
(2 mg/ml; Sigma-Aldrich) and mounted on glass slides with mounting medium
(Dako). In the case of mitochondrial staining, the Mitotracker Red CMXRos
probe (Life Technologies) (300 nM) was incubated with HxIP-treated
cells for 0.5 hr prior to visualization or followed by cell fixation and
permeabilization.
Confocal Microscopy
Cell nuclei and protein levels were visualized by confocal microscopy (objec-
tive 340, Leica TCS SP2). Nuclear images were acquired by sequential862–875, July 23, 2015 ª2015 Elsevier Ltd All rights reserved 873
scanning using the LAS AF Lite program. In the case of HxIP detection only, the
blue fluorescent HxIP was excited with a UV laser (364 nm) and detected using
the DAPI filter. PI was excited with the 488 line of an argon-ion laser and de-
tected at 642 nm. The fluorescence of the drug was detected and imaged
by z-stack acquisition using the Zeiss 510 UV-vis microscope with LSM510
software. In all cases the operating conditions were such that detectable sig-
nals of HxIP could not be obtained for cell samples not treated with the poly-
amide. In the case of g-H2Ax detection, the number of foci was quantified us-
ing CellProfiler software (Lamprecht et al., 2007). For all statistical analysis of
significance, the paired, one-tailed Student t test was utilized with p < 0.05
considered significant.
MoFlo Legacy Cell Sorting
Cells were allowed to grow to confluency in 6-well plate dishes (Corning)
and treated with different HxIP concentrations for incubation times ranging
from 5 min to 24 hr. After treatment the cells were trypsinized, fixed with 4%
PFA, washed repeatedly with PBS, and passaged through a cell strainer
(BD falcon). Finally, cells were permeabilized and stained with PI (2 mg/ml).
HxIP fluorescence was detected through excitation with the use of a UV
laser, and detected with a 420/40 bandpass filter. Data were analyzed using
Summit version 4.3 (Beckman Coulter). PI was detected with a 613/20
bandpass filter.
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